查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957591

2026年全球胜肽和寡核苷酸CDMO市场报告

Peptide And Oligonucleotide CDMO Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，胜肽和寡核苷酸CDMO的市场规模迅速扩张。预计该市场规模将从2025年的24.2亿美元成长到2026年的27亿美元，复合年增长率（CAGR）为11.9%。过去几年的成长主要归因于胜肽类药物的推广应用、合成寡核苷酸复杂性的增加、製药公司内部生产能力的局限性、监管合规要求的日益严格以及反义和肽类药物的早期应用。

预计未来几年胜肽和寡核苷酸CDMO市场将快速成长，到2030年将达到40.3亿美元，复合年增长率（CAGR）为10.5%。预测期内的成长要素包括寡核苷酸治疗产品线的扩展、对罕见疾病和癌症治疗投资的增加、对快速临床试验材料生产的需求不断增长、对专业CDMO伙伴关係的偏好日益增强以及固相合成技术的进步。预测期内的关键趋势包括胜肽和寡核苷酸生产的外包增加、对符合CGMP规范的复杂分子生产的需求不断增长、端到端开发和生产服务的增强、对高活性、高纯度治疗药物的日益关注以及可扩展和灵活的生产平台的日益普及。

个人化医疗的日益普及预计将推动胜肽和寡核苷酸CDMO市场的成长。个人化医疗是一种根据个人特征（例如遗传因素、环境和生活方式）客製化医疗方案和治疗方法的医疗策略。这一增长受到多种因素的驱动，包括基因组分析技术的进步、分子层面疾病路径的阐明，以及针对每位患者独特遗传背景和健康记录量身定制的精准有效治疗方法的需求。胜肽和寡核苷酸的合约开发和生产机构（CDMO）在这一领域发挥着至关重要的作用，它们能够开发出适合特定患者需求的客製化治疗性胜肽和寡核苷酸。例如，总部位于英国的个人化医疗联盟于2024年2月宣布，美国食品药物管理局（FDA）药物评估与研究中心（CDER）已核准16种用于治疗罕见疾病患者的新型个人化疗法。与 2022 年获批的 6 个项目相比，这是一个显着的成长。因此，个人化医疗的快速发展正在推动胜肽和寡核苷酸 CDMO 市场的扩张。

胜肽和寡核苷酸CDMO市场的主要企业正优先考虑策略合作伙伴关係，以拓展服务组合、提升技术专长并扩大市场影响。胜肽开发和生产合作伙伴关係是指旨在开发和生产肽类治疗药物的组织间达成的合作协议。例如，2023年5月，总部位于美国的合约开发和生产组织（CDMO）PolyPeptide Group AG与德国生物技术公司Numaferm GmbH达成合作，共同开发和生产胜肽类药物。此次合作充分利用了PolyPeptide的cGMP生产能力和市场覆盖范围，以及Numaferm的环保胜肽生产技术和生化平台技能。该合作的核心是共同开发有前景的候选胜肽，并致力于实现更永续肽类原料药（API）生产。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球胜肽和寡核苷酸CDMO市场：吸引力评分和分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 永续性、气候技术、循环经济
  • 主要趋势
    • 胜肽和寡核苷酸生产外包增加
    • 对符合CGMP规范的复杂分子生产的需求日益增长
    • 扩展端到端开发和製造服务
    • 人们越来越关注高效高纯度的治疗药物
    • 扩大具有扩充性和柔软性的製造平台的应用范围

第五章 终端用户产业市场分析

  • 生物製药公司
  • 製药公司
  • 研究机构
  • 学术机构及政府机构
  • 处于临床阶段的生物技术公司

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球胜肽和寡核苷酸CDMO市场：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球胜肽和寡核苷酸CDMO市场规模、比较和成长率分析
  • 全球胜肽和烷基化合物开发与生产组织（CDMO）市场表现：规模和成长，2020-2025年
  • 全球胜肽和寡核苷酸CDMO市场预测：规模和成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 副产品
  • 胜肽、寡核苷酸
  • 按服务类型
  • 合约开发，契约製造
  • 透过使用
  • 治疗药物、研究应用、诊断试剂及其他用途
  • 最终用户
  • 生物製药公司、製药公司、研究机构、学术和政府机构以及其他最终用户
  • 按类型细分：胜肽
  • 药物原料药（原料药）、胜肽类药物、胜肽合成及生产服务
  • 按型别细分：寡核苷酸
  • 反义寡核苷酸、siRNA 和 mRNA 寡核苷酸、寡核苷酸合成和生产服务

第十章 区域与国别分析

  • 全球胜肽和寡核苷酸CDMO市场：按地区划分，历史数据和预测，2020-2025年，2025-2030年预测，2035年预测
  • 全球胜肽和寡核苷酸CDMO市场：按国家/地区划分，历史数据和预测数据（2020-2025年、2025-2030年预测、2035年预测）。

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 胜肽和寡核苷酸CDMO市场：竞争格局和市场份额，2024年
  • 胜肽和寡核苷酸CDMO市场：公司估值矩阵
  • 胜肽和寡核苷酸CDMO市场：公司概况
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Ajinomoto Co. Inc.
    • Lonza Group AG
    • WuXi AppTec Co. Ltd.

第37章 其他大型企业和创新企业

  • Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA, CordenPharma International, Bachem Holding AG, GenScript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, AmbioPharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年胜肽和寡核苷酸CDMO市场：提供新机会的国家
  • 2030年胜肽和寡核苷酸CDMO市场：提供新机会的细分市场
  • 胜肽和寡核苷酸CDMO市场2030：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH3MPOCL01_G26Q1

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) is a company offering services for the development, manufacturing, and supply of peptide- and oligonucleotide-based therapeutics. These organizations deliver specialized knowledge in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to enable production of peptides and oligonucleotides for diverse clients.

The primary product categories for peptide and oligonucleotide CDMOs consist of peptides and oligonucleotides. Peptides are brief sequences of amino acids, generally under 50 in length, which serve key functions in biological activities like signaling and hormone control. They offer services including contract development and contract manufacturing. These find use in areas such as therapeutics, research tools, diagnostics, and more, serving end-users like biopharmaceutical firms, pharmaceutical companies, research institutions, academic and government bodies, and others.

Tariffs have affected the peptide and oligonucleotide CDMO market by increasing costs for imported raw materials, reagents, synthesis equipment, and specialized consumables used in manufacturing. These impacts are most pronounced in contract manufacturing services and therapeutic applications, particularly in regions dependent on cross-border chemical supply chains such as North America and Europe. Higher costs have pressured pricing and extended development timelines. However, tariffs have also encouraged localization of manufacturing, supplier diversification, and investments in domestic production capabilities.

The peptide and oligonucleotide cdmo market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide cdmo market statistics, including peptide and oligonucleotide cdmo industry global market size, regional shares, competitors with a peptide and oligonucleotide cdmo market share, detailed peptide and oligonucleotide cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. This peptide and oligonucleotide cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.42 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to growth in peptide-based therapeutics, increasing complexity of synthetic oligonucleotides, limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, early adoption of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.

The increasing uptake of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine represents a healthcare strategy that customizes medical choices and therapies based on individual factors like genetics, environment, and lifestyle. This rising adoption stems from various drivers, including progress in genomic tools, deeper insights into molecular disease pathways, and the need for precise, effective treatments matched to patients' unique genetic backgrounds and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in this field, as they create bespoke therapeutic peptides and oligonucleotides suited to specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition-a UK organization advocating for personalized medicine-noted that the FDA's Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized therapies for rare disease patients, compared to just 6 in 2022. Thus, the surge in personalized medicine is propelling the peptide and oligonucleotide CDMO market.

Major companies in the peptide and oligonucleotide CDMO market are prioritizing strategic partnerships to improve their service portfolios, bolster technological expertise, and broaden market presence. Peptide development and production partnerships involve collaborative deals between organizations aimed at creating and producing peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), teamed up with Numaferm GmbH, a Germany-based biotech firm, for peptide development and production. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's skills in eco-friendly peptide manufacturing and biochemical platforms. The collaboration centers on co-developing promising peptide candidates to enable more sustainable production of peptide-based APIs.

In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed sum. The deal aimed to strengthen EUROAPI's standing in the contract development and manufacturing organization (CDMO) market for oligonucleotides, building on its existing capacity in Frankfurt. BianoGMP, a Germany-based contract development and manufacturing organization (CDMO), specializes in analytical services for oligonucleotides.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Other End Users
  • Subsegments:
  • 1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
  • 2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.; Catalent Inc.; Piramal Pharma Ltd; Curia Global Inc.; Almac Group; Euroapi SA.; CordenPharma International; Bachem Holding AG; Genscript Biotech Corporation; PolyPeptide Group; Rentschler Biopharma SE; Ambiopharm Inc; ScinoPharm; Senn Chemicals AG; Aurigene Pharmaceutical Services; Creative Peptides; Sylentis S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Peptide And Oligonucleotide CDMO Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Peptide And Oligonucleotide CDMO Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Peptide And Oligonucleotide CDMO Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Peptide And Oligonucleotide CDMO Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Outsourcing Of Peptide And Oligonucleotide Manufacturing
    • 4.2.2 Growing Demand For Cgmp-Compliant Complex Molecule Production
    • 4.2.3 Expansion Of End-To-End Development And Manufacturing Services
    • 4.2.4 Increased Focus On High-Potency And High-Purity Therapeutics
    • 4.2.5 Greater Adoption Of Scalable And Flexible Manufacturing Platforms

5. Peptide And Oligonucleotide CDMO Market Analysis Of End Use Industries

  • 5.1 Biopharmaceutical Companies
  • 5.2 Pharmaceutical Companies
  • 5.3 Research Institutes
  • 5.4 Academic And Government Organizations
  • 5.5 Clinical-Stage Biotechnology Companies

6. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide And Oligonucleotide CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Peptide And Oligonucleotide CDMO Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide And Oligonucleotide CDMO Market Segmentation

  • 9.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Peptides, Oligonucleotides
  • 9.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Contract Development, Contract Manufacturing
  • 9.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Therapeutics, Research Applications, Diagnostics, Other Applications
  • 9.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
  • 9.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
  • 9.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

10. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 10.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 11.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide And Oligonucleotide CDMO Market

  • 12.1. China Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide And Oligonucleotide CDMO Market

  • 13.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide And Oligonucleotide CDMO Market

  • 14.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide And Oligonucleotide CDMO Market

  • 15.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide And Oligonucleotide CDMO Market

  • 16.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide And Oligonucleotide CDMO Market

  • 17.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide And Oligonucleotide CDMO Market

  • 18.1. Taiwan Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide And Oligonucleotide CDMO Market

  • 19.1. South East Asia Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide And Oligonucleotide CDMO Market

  • 20.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide And Oligonucleotide CDMO Market

  • 21.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide And Oligonucleotide CDMO Market

  • 22.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide And Oligonucleotide CDMO Market

  • 23.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide And Oligonucleotide CDMO Market

  • 24.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide And Oligonucleotide CDMO Market

  • 25.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 26.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide And Oligonucleotide CDMO Market

  • 27.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide And Oligonucleotide CDMO Market

  • 28.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide And Oligonucleotide CDMO Market

  • 29.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide And Oligonucleotide CDMO Market

  • 30.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide And Oligonucleotide CDMO Market

  • 31.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide And Oligonucleotide CDMO Market

  • 32.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide And Oligonucleotide CDMO Market

  • 33.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide And Oligonucleotide CDMO Market

  • 34.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide And Oligonucleotide CDMO Market Regulatory and Investment Landscape

36. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 36.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Peptide And Oligonucleotide CDMO Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA, CordenPharma International, Bachem Holding AG, GenScript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, AmbioPharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides

38. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

40. Peptide And Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies

  • 40.1 Peptide And Oligonucleotide CDMO Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Peptide And Oligonucleotide CDMO Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Peptide And Oligonucleotide CDMO Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer